Retour
Trevi Therapeutics Inc (TRVI) Gagner
Graphique du cours de l'action TRVI
TRVI Gagner
Trevi Therapeutics Inc
$11.94
3.1%
$0.35
À la fermeture : Apr 02, 16:00:00 GMT-4
$12.18
2.01%
$0.24
Post-Marché: Apr 02, 20:00:00 GMT-4
Statistiques clés
Clôture préc.
$11.58
Prix d'ouverture
$11.33
Plage de la journée
$11.26 - $12.28
Plage de 52 semaines
$4.85 - $14.39
Volume
1.1M
Volume moyen
1.3M
Rendement en dividend
--
BPA (TTM)
-0.37
Capitalisation boursière
$1.5B
Qu’est-ce que TRVI ?
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is headquartered in New Haven, Connecticut. The company went IPO on 2019-05-07. The firm is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. The company has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Fonctionnalités
Ressources
© 2026 Finture Development Limited. Tous droits réservés.